---
title: "Zepbound (tirzepatide), all indications: Specific populations questions"
description: "Specific populations questions on Zepbound (tirzepatide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Can Zepbound be used during pregnancy? Can Zepbound be used while breastfeeding? Can children or teenagers take Zepbound? Is a Zepbound dose change needed for kidney or liver impairment? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/zepbound/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Zepbound (tirzepatide), all indications: Specific populations questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Zepbound](https://uspl.lilly.com/zepbound/zepbound.html#pi)  
Indication pages: [Chronic weight management](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management)

## Specific populations

<a id="zepbound-pregnancy"></a>

### Can Zepbound be used during pregnancy?

> “Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized (see Clinical Considerations). Available data with tirzepatide in pregnant patients are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Weight%20loss%20offers%20no%20benefit,exposure%20to%20tirzepatide%20during%20pregnancy.)

> “Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those with obesity or overweight, due to the obligatory weight gain that occurs in maternal tissues during pregnancy.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Appropriate%20weight%20gain%20based%20on,in%20maternal%20tissues%20during%20pregnancy.)

> “There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ZEPBOUND (tirzepatide) during pregnancy. Pregnant patients exposed to ZEPBOUND and healthcare providers are encouraged to register by calling 1-844-524-0039 or emailing at MILEregistry@thermofisher.com. To learn more please call or visit https://pregnancyregistry.lilly.com/zepbound.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=There%20is%20a%20pregnancy%20exposure,please%20call%20or%20visit%20https%3A%2F%2Fpregnancyregistry.lilly.com%2Fzepbound.)

<a id="zepbound-breastfeeding"></a>

### Can Zepbound be used while breastfeeding?

> “In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose (see Data). There are no available data on the effects of tirzepatide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZEPBOUND and any potential adverse effects on the breastfed infant from ZEPBOUND or from the underlying maternal condition.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20a%20single%2Ddose%20clinical%20lactation,from%20the%20underlying%20maternal%20condition.)

> “Following subcutaneous administration of a single 5 mg dose to 11 healthy lactating adult females, the concentration of tirzepatide in breast milk was found to be undetectable (limit of detection in breast milk 4 ng/mL) in 164/171 samples assayed. The cumulative amount of tirzepatide detected in the remaining 7 breast milk samples over the 28-day sampling window was equivalent to less than 0.02% of the maternal administered dose, with the last measurable concentrations occurring 5 days post-dose. The AUC of tirzepatide in breast milk could not be calculated, due to insufficient quantifiable concentrations.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Following%20subcutaneous%20administration%20of%20a,due%20to%20insufficient%20quantifiable%20concentrations.)

<a id="zepbound-children"></a>

### Can children or teenagers take Zepbound?

> “The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=The%20safety%20and%20effectiveness%20of,been%20established%20in%20pediatric%20patients.)

<a id="zepbound-kidney-liver-dosing"></a>

### Is a Zepbound dose change needed for kidney or liver impairment?

> “No dosage adjustment of ZEPBOUND is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no change in tirzepatide pharmacokinetics (PK) was observed [see Clinical Pharmacology (12.3)]. Monitor renal function in patients reporting adverse reactions to ZEPBOUND that could lead to volume depletion [see Warnings and Precautions (5.3)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=No%20dosage%20adjustment%20of%20ZEPBOUND,%5Bsee%20Warnings%20and%20Precautions%20%285.3%29%5D.)

> “No dosage adjustment of ZEPBOUND is recommended for patients with hepatic impairment. In a clinical pharmacology study in subjects with varying degrees of hepatic impairment, no change in tirzepatide PK was observed [see Clinical Pharmacology (12.3)].”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=8.7%20Hepatic%20Impairment-,No%20dosage%20adjustment%20of%20ZEPBOUND%20is%20recommended%20for%20patients%20with,observed%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

<a id="zepbound-overdose"></a>

### What should be done after a Zepbound overdose?

> “In the event of an overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms. A period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5 days.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20the%20event%20of%20an,tirzepatide%20of%20approximately%205%20days.)

## Related pages
- [Medical information: Zepbound (tirzepatide): All indications](https://www.evicenter.com/medical-information/zepbound)
- [Indication](https://www.evicenter.com/medical-information/zepbound/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/zepbound/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/zepbound/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/zepbound/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/zepbound/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/zepbound/storage-and-supply)
